INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

CNW/ - Pharmascience Canada is proud to announce the launch of  Pr  pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.